WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018029213) HISTONES AND/OR PROADM AS MARKERS INDICATING ORGAN DYSFUNCTION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/029213    International Application No.:    PCT/EP2017/070111
Publication Date: 15.02.2018 International Filing Date: 08.08.2017
IPC:
G01N 33/68 (2006.01), G01N 33/74 (2006.01)
Applicants: B.R.A.H.M.S GMBH [DE/DE]; Neuendorfstraße 25 16761 Hennigsdorf (DE)
Inventors: ZIERA, Tim; (DE).
DREYER, Frauke; (DE).
INCAMPS, Anne; (FR).
KROP, Manne; (DE).
CHARLES, Pierre-Emmanuel; (FR)
Agent: VOSSIUS & PARTNER (NO 31); Siebertstraße 3 81675 München (DE)
Priority Data:
16183376.9 09.08.2016 EP
Title (EN) HISTONES AND/OR PROADM AS MARKERS INDICATING ORGAN DYSFUNCTION
(FR) HISTONES ET/OU PROADM EN TANT QUE MARQUEURS INDIQUANT UN DYSFONCTIONNEMENT D’ORGANE
Abstract: front page image
(EN)The present invention relates to the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of organ dysfunction in a subject. The invention relates to a method that comprises determining a level of at least one histone, particularly H2B, H4, H2A and/or H3, in a sample of said subject and wherein said level of at least one histone is indicative of said organ dysfunction. Further, the invention relates to a method that comprises determining a level of proadrenomedullin (proADM), particularly midregional proadrenomedullin (MR-proADM), in a sample of said subject and wherein said level of proADM is indicative of said organ dysfunction. The invention further relates to kits for carrying out the methods of the invention.
(FR)La présente invention concerne le diagnostic, le pronostic, l’évaluation des risques, la stratification des risques, la surveillance, le guidage thérapeutique et/ou le contrôle thérapeutique d’un dysfonctionnement d’organe chez un sujet. L’invention concerne un procédé qui comprend la détermination d’un taux d’au moins une histone, en particulier H2B, H4, H2A et/ou H3, dans un échantillon dudit sujet et ledit taux d’au moins une histone étant indicatif dudit dysfonctionnement d’organe. L’invention concerne en outre un procédé qui comprend la détermination d’un taux de proadrénomédulline (proADM), en particulier de proadrénomédulline de région médiane (MR-proADM), dans un échantillon dudit sujet et ledit taux de proADM étant indicatif dudit dysfonctionnement d’organe. L’invention concerne en outre des trousses pour conduire les procédés de l’invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)